These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 25397521)

  • 1. Who gets single tablet regimens (STR), and why?
    Tarrier L; Kegg S
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19777. PubMed ID: 25397521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability is more important than simplicity for treatment durability.
    Trottier B; Machouf N; Huchet E; Lavoie S; Vezina S; Boissonnault M; Charest L; Munoz M; Legault D; Longpré D; Thomas R
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19765. PubMed ID: 25397509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rate of viral load failure over time in people on ART in the UK Collaborative HIV Cohort (CHIC) study.
    O'Connor J; Smith C; Lampe F; Johnson M; Sabin C; Phillips A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19527. PubMed ID: 25394036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapy.
    Blanco JL; Montaner JS; Marconi VC; Santoro MM; Campos-Loza AE; Shafer RW; Miller MD; Paredes R; Harrigan R; Nguyen ML; Perno CF; Gonzalez-Hernandez LA; Gatell JM
    AIDS; 2014 Nov; 28(17):2531-9. PubMed ID: 25574957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Four-drugs regimen containing raltegravir is highly effective in HIV patients starting therapy with >500,000 copies/mL viral load.
    Sterrantino G; Zaccarelli M; Prati F; Boschi A; Sighinolfi L; Borghi V
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19774. PubMed ID: 25397518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
    Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
    Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching to nevirapine-based regimens after undetectable viral load is not associated with increased risk of discontinuation due to toxicity.
    Patterson P; Socías E; Pryluka D; Lapadula P; Pérez H; Cahn P
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19794. PubMed ID: 25397538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of time to undetectable HIV viral load in the first 16 weeks after the start of three and four antiretroviral regimens.
    Manavi K; Scott G
    Int J STD AIDS; 2006 Aug; 17(8):522-4. PubMed ID: 16925897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes.
    Potard V; Rey D; Mokhtari S; Frixon-Marin V; Pradier C; Rozenbaum W; Brun-Vezinet F; Costagliola D;
    Antivir Ther; 2007; 12(3):317-24. PubMed ID: 17591021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to HIV treatment regimens: systematic literature review and meta-analysis.
    Altice F; Evuarherhe O; Shina S; Carter G; Beaubrun AC
    Patient Prefer Adherence; 2019; 13():475-490. PubMed ID: 31040651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of HIV-1 drug resistance in treatment-naïve patients and its clinical implications in an antiretroviral treatment program in Cameroon.
    Zoufaly A; Jochum J; Hammerl R; Nassimi N; Raymond Y; Burchard GD; Schmiedel S; Drexler JF; Kay CN; Taka N; Awasom C; Metzner K; Jan vL; Feldt T
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19615. PubMed ID: 25394119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients' willingness to take separate component antiretroviral therapy regimens for HIV in the Netherlands.
    Engelhard E; Smith C; Vervoort S; Kroon F; Brinkman K; Nieuwkerk P; Reiss P; Geerlings S
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19536. PubMed ID: 25394045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment.
    Sweet D; Song J; Zhong Y; Signorovitch J
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19537. PubMed ID: 25394046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens.
    Giacomelli A; Oreni L; Franzetti M; Di Cristo V; Vergani B; Morosi M; Colella E; Galli M; Rusconi S
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19830. PubMed ID: 25397574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.
    Clevenbergh P; Boulmé R; Kirstetter M; Dellamonica P
    HIV Med; 2004 Jul; 5(4):284-8. PubMed ID: 15236618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study.
    Gantner P; Reinhart S; Partisani M; Baldeyrou M; Batard ML; Bernard-Henry C; Cheneau C; de Mautort E; Priester M; Fafi-Kremer S; Muret P; Rey D
    HIV Med; 2015 Feb; 16(2):132-6. PubMed ID: 25124291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.